NCT01283516 - A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

January 24, 2011

Primary Completion Date

May 3, 2016

Study Completion Date

May 3, 2016

Conditions

Tumors Characterized by Genetic Abnormalities of ALK

Interventions

DRUG

LDK378

LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.

Trial Locations (21)

3000

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Leuven

10017

Memorial Sloan Kettering MSK, New York

19111

Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia

20089

Novartis Investigative Site, Rozzano

20141

Novartis Investigative Site, Milan

45147

Novartis Investigative Site, Essen

50937

Novartis Investigative Site, Cologne

69120

Novartis Investigative Site, Heidelberg

80045

University of Colorado School of Medicine Colorado Univ, Aurora

84103

University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City

89081

Novartis Investigative Site, Ulm

98105

Seattle Cancer Care Alliance, Seattle

169610

Novartis Investigative Site, Singapore

02114

Massachusetts General Hospital Mass General, Boston

M5G 1Z6

Novartis Investigative Site, Toronto

1066 CX

Novartis Investigative Site, Amsterdam

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

G12 0YN

Novartis Investigative Site, Glasgow

LE1 5WW

Novartis Investigative Site, Leicester